Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. Gadi D, et al. Among authors: fisher dc. Leukemia. 2022 Mar;36(3):723-732. doi: 10.1038/s41375-021-01441-9. Epub 2021 Nov 6. Leukemia. 2022. PMID: 34743191 Free PMC article. Clinical Trial.
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA. Friedberg JW, et al. Among authors: fisher dc. Leuk Res. 2004 Feb;28(2):139-47. doi: 10.1016/s0145-2126(03)00213-3. Leuk Res. 2004. PMID: 14654078 Clinical Trial.
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Brown JR, et al. Among authors: fisher dc. Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64. doi: 10.1016/j.bbmt.2006.06.004. Biol Blood Marrow Transplant. 2006. PMID: 17084369 Free article.
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Armand P, et al. Among authors: fisher dc. Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008. Biol Blood Marrow Transplant. 2008. PMID: 18342784 Free PMC article.
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Armand P, et al. Among authors: fisher dc. J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001324 Free PMC article.
200 results